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Background: Children with increased pulmonary blood flow may experi-
ence morbidity as the result of increased pulmonary vascular resistance
after operations in which cardiopulmonary bypass is used. Plasma lev-
els of endothelin-1, a potent vasoactive substance implicated in pul-
monary hypertension, are increased after cardiopulmonary bypass.
Objectives: In a lamb model of increased pulmonary blood flow after in
utero placement of an aortopulmonary shunt, we characterized the
changes in pulmonary vascular resistance induced by hypothermic car-
diopulmonary bypass and investigated the role of endothelin-1 and
endothelin-A receptor activation in postbypass pulmonary hyperten-
sion. Methods: In eleven 1-month-old lambs, the shunt was closed, and
vascular pressures and blood flows were monitored. An infusion of a
selective endothelin-A receptor blocker (PD 156707; 1.0 mg/kg/h) or
drug vehicle (saline solution) was then begun 30 minutes before car-
diopulmonary bypass and continued for 4 hours after bypass. The
hemodynamic variables were monitored, and plasma endothelin-1 con-
centrations were determined before, during, and for 6 hours after car-
diopulmonary bypass. Results: After 90 minutes of hypothermic cardio-
pulmonary bypass, both pulmonary arterial pressure and pulmonary
vascular resistance increased significantly in saline-treated lambs dur-
ing the 6-hour study period (P < .05). In lambs pretreated with PD
156707, pulmonary arterial pressure and pulmonary vascular resistance
decreased (P < .05). After bypass, plasma endothelin-1 concentrations
increased in all lambs; there was a positive correlation between postby-
pass pulmonary vascular resistance and plasma endothelin-1 concen-
trations (P < .05). Conclusions: This study suggests that endothelin-A
receptor–induced pulmonary vasoconstriction mediates, in part, the rise
in pulmonary vascular resistance after cardiopulmonary bypass.
Endothelin-A receptor antagonists may decrease morbidity in children
at risk for postbypass pulmonary hypertension. This potential therapy
warrants further investigation. (J Thorac Cardiovasc Surg 1999;117:
314-23)
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T he development of pulmonary hypertension is acommon accompaniment of congenital heart dis-
ease with increased pulmonary blood flow.1 Although
early surgical repair of these congenital heart defects
has decreased the incidence of irreversible pulmonary
vascular disease, those children with reversible vascu-
lar changes experience morbidity and death in the post-
operative period as the result of elevations in pul-
monary vascular resistance and increased pulmonary
vascular reactivity immediately after cardiopulmonary
bypass (CPB).2 Although increases in pulmonary vas-
cular resistance and pulmonary vascular reactivity after
CPB are well described, their mechanisms remain
incompletely understood. 
Recent evidence suggests that pulmonary vascular
tone is regulated by a complex interaction of vasoactive
substances that are locally produced by the vascular
endothelium.3 During CPB, pulmonary vascular endo-
thelial injury secondary to a variety of factors, includ-
ing the disruption of normal pulmonary blood flow,
complement activation, and neutrophil activation, may
contribute to pulmonary hypertension after CPB.4,5
Endothelin-1 (ET-1) is a 21 amino acid polypeptide
produced by vascular endothelial cells, the potent
vasoactive properties of which have been implicated in
the pathophysiology of pulmonary hypertensive disor-
ders.6 The hemodynamic effects of ET-1 are mediated
by at least 2 distinctive receptor populations, ETA and
ETB.7 The ETA receptors and a subpopulation of ETB
receptors mediate vasoconstriction and are located on
vascular smooth muscle cells. A second subpopulation
of ETB receptors mediates vasodilatation and is located
on vascular endothelial cells.7 In patients with congen-
ital heart disease and pulmonary hypertension, plasma
concentrations of ET-1 are increased immediately after
CPB.8 Therefore alterations in ET-1 induced during
CPB may be responsible, in part, for the increased pul-
monary vascular resistance and increased vascular
reactivity noted in children immediately after cardiac
surgery.
We have established a model of pulmonary hyperten-
sion with increased pulmonary blood flow in the lamb,
after in utero placement of an aorta-to-pulmonary vas-
cular graft. At 1 month of age, these lambs (shunted
lambs) have a pulmonary-to-systemic blood flow ratio
of approximately 2:1, a mean pulmonary arterial pres-
sure that is 75% of mean systemic arterial pressure, and
pulmonary vascular remodeling characteristic of chil-
dren with pulmonary hypertension and increased pul-
monary blood flow.11 The purpose of the present study
was to use our animal model to characterize the
changes in pulmonary vascular resistance induced by
hypothermic CPB and to specifically investigate the
role of ETA receptor activation in pulmonary hyperten-
sion after CPB. To characterize the changes in pul-
monary vascular resistance induced by CPB, we moni-
tored the hemodynamic response of the pulmonary
circulation, in 5 one-month-old shunted lambs, for 6
hours after 90 minutes of hypothermic CPB. To assess
the role of ET-1 and ETA receptor activation in pul-
monary hypertension after CPB, we determined the
effects of ETA receptor blockade on the hemodynamic
response of the pulmonary circulation to CPB in an
additional 6 shunted lambs and measured the plasma
levels of ET-1 before and after CPB in all 11 lambs.
Methods
Surgical preparations and care
Ewes. Eleven mixed-breed Western pregnant ewes (139.7 ±
2.8 days of gestation; term, 145 days) were operated on under
sterile conditions as previously described.9 Through a left lat-
eral fetal thoracotomy, an 8.0 mm polytetrafluoroethylene*
vascular graft (approximately 2 mm in length) was anasto-
mosed between the ascending aorta and main pulmonary
artery of the fetus with 7-0 proline (Ethicon Inc, Somerville,
NJ), with a continuous suture technique as previously
described.9 After recovery from anesthesia, the ewe was
returned to the cage with free access to food and water.
Antibiotics (2 million units of penicillin G potassium and 100
mg of gentamicin sulfate) were administered to the ewe dur-
ing the operation and daily thereafter until 2 days after spon-
taneous delivery of the lamb.
Lambs. After spontaneous delivery, the lambs were treated
with antibiotics (1 million units of penicillin G potassium and
25 mg of gentamicin sulfate, intramuscularly) for 2 days. The
lambs were weighed daily, and the respiratory rate and heart
rate were obtained. Furosemide (1 mg/kg, intramuscularly)
was administered daily. Elemental iron (50 mg, intramuscu-
larly) was given weekly.
At 1 month of age, 11 shunted lambs were anesthetized with
ketamine hydrochloride (approximately 1 mg/kg/min) and
mechanically ventilated as previously described.10,11 Through
a midsternotomy incision, polyurethane catheters were insert-
ed into the left and right atria and the main pulmonary artery
distal to the vascular graft. Ultrasonic flow probes (Transonics
Systems Inc, Ithaca, NY) were placed around the left and right
pulmonary arteries to measure pulmonary blood flow. After a
30-minute recovery, blood was obtained from the left and
right atria, distal pulmonary artery, right ventricle, and
descending aorta for hemoglobin and oxygen saturation deter-
minations. A vascular clamp was then placed on the graft to
completely occlude it, and oxygen saturation determinations
were obtained from the right ventricle and distal pulmonary
artery to document shunt closure. The sternum was then tem-
*W.L. Gore and Associates, Inc, Newark, Del.
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porarily approximated. An intravenous injection of 250,000
units of penicillin G potassium and 25 mg of gentamicin sul-
fate suspension was administered. 
CPB. The bypass circuit is similar to the standard neonatal
circuit.12 It consists of a membrane oxygenator (Minimax;
Medtronic, Inc, Grand Rapids, Mich), an infant venous reser-
voir (Medtronic, Inc), an arterial filter (40 m m; Bentley, Irvine,
Calif), and a cardiotomy reservoir and suction. An ultrasonic
flow probe (Transonics Systems Inc) is incorporated into the
circuit to monitor pump flows continuously. The circuit is
primed with fresh heparinized sheep whole blood (400 mL),
crystalloid (Normosol; 600 mL), heparin (2500 units), sodium
bicarbonate (10 mEq), methylprednisolone sodium succinate
(Solu-Medrol; 30 mg/kg), and cefazolin (Kefzol; 25 mg/kg).
The bypass method is similar to standard neonatal methods.12
Heparin (300 U/kg) was administered to the lamb in the right
atrium. Bicaval venous cannulation was performed with a 16F
venous cannula (DLB Inc, Grand Rapids, Mich) for the supe-
rior vena cava and a 20F venous cannula for the inferior vena
cava. The ascending aorta was cannulated with a 14F cannula
(Electro-catheter Corp, Rahway, NJ). CPB was begun, and
surface and core cooling was initiated. The sternum was again
temporarily approximated. Normothermic flows ranged from
150 to 200 mL/kg/min. The lambs were cooled to 25°C, and
flow was reduced to 100 mL/kg/min. After 60 minutes at
25°C, rewarming was started. Throughout the CPB period, an
alpha stat blood gas strategy was maintained, whereby the
temperature-uncorrected PaCO2 is maintained near 40 mm Hg
(measured at 37°C) and the temperature-uncorrected pH is
maintained near 7.40, irrespective of body temperature.13
Mannitol (0.5 gm/kg) and furosemide (0.5 mg/kg) were added
to the prime at the onset of rewarming. After the core temper-
ature reached 32°C, calcium gluconate (1 g) was added to the
prime. After the lambs were rewarmed, ventilation was
resumed and CPB was weaned off. Heparin was completely
reversed with protamine (3 mg/kg) given into the left atrium.
Measurements. Pulmonary and systemic arterial and right
and left atrial pressures were measured with pressure trans-
ducers (P23Db; Statham Instruments, Hato Rey, Puerto
Rico). Mean pressures were obtained by electrical integra-
tion. Heart rate was measured by a cardiotachometer trig-
gered from the phasic systemic arterial pressure pulse wave.
Left and right pulmonary blood flow and bypass flows were
measured on an ultrasonic flow meter (Transonic Systems
Inc). All hemodynamic variables were recorded continuously
on a multichannel electrostatic recorder (Gould Inc,
Cleveland, Ohio). Systemic arterial blood gases and pH were
measured on a pH/blood gas analyzer (Corning 158; Corning
Medical and Scientific, Medfield, Mass). Hemoglobin con-
centration and oxygen saturation were measured by a hemox-
imeter (model OSM 2; Radiometer, Copenhagen, Denmark).
The ratio of pulmonary to systemic blood flow was calculat-
ed with the Fick equation. After shunt closure, systemic
blood flow was defined as total pulmonary blood flow.
Pulmonary and systemic vascular resistances were calculated
with standard formulas. 
ET-1 determinations. Four milliliters of systemic arterial
blood was collected and placed in iced polypropylene tubes
containing 330 m L aprotinin and 100 m L EDTA. The tubes
were immediately centrifuged at 4000g for 20 minutes.
Collected plasma was treated with equal volumes of 0.1% tri-
fluoroacetic acid and stored at –70°C. The acidified super-
natant was centrifuged at 1000g for 20 minutes and loaded on
a 3 · 18 C18 Sep-Pak column (Peninsula Laboratories,
Belmont, Calif) equilibrated with 0.1% trifluoroacetic acid.
The adsorbed material was eluted with 3 mL of 0.1% trifluo-
roacetic acid/60% acetronitrile. The eluant was dried in a
Savant speed vacuum and stored at –70°C or assayed imme-
diately for immunoreactive endothelin. ET-1 standard, ET-1
labeled with iodine 125, anti-ET antibody, and secondary anti-
body were purchased from Peninsula Laboratories, Belmont,
Calif. Cross-reactivity for measured human and bovine ET-1
antiserum is 100% for human ET-1, 7% for human ET-2 and
ET-3, and 0% for bovine ET-2 and ET-3. Interassay and intra-
assay variabilities were 10% and 4%, respectively. Plasma
levels were not corrected for hemodilution. 
PD 156707 determinations. Two milliliters of systemic
arterial blood were collected and immediately centrifuged at
4000g for 20 minutes. Collected plasma was stored at –70°C.
Plasma concentrations were determined by a liquid chro-
matographic assay, as previously described.14
Experimental protocol. Sixty minutes after shunt and chest
closure, baseline measurements of the hemodynamic vari-
ables (pulmonary and systemic arterial pressure, heart rate,
pulmonary blood flow, left and right atrial pressures), and
systemic arterial blood gases and pH were measured. Then an
infusion of PD 156707, a selective ETA receptor blocker (1
mg/kg/h; synthesized by the Medicinal Chemistry
Department, Parke-Davis Pharmaceutical Research, Ann
Arbor, Mich), or drug vehicle (saline solution; randomly
selected) was begun and continued during CPB and for 4
hours after CPB.15 The dose of PD 156707 was chosen after
several preliminary studies showed that a 30-minute infusion
completely blocked the vasoconstricting effects of exogenous
ET-1 and resulted in steady-state plasma concentrations that
blocked ETA receptors in vivo.16 Thirty minutes after the ini-
tiation of the infusion, all measurements were repeated
(before bypass) and CPB was begun. The hemodynamic vari-
ables were monitored continuously during and for 6 hours
after CPB. Systemic arterial blood gases were determined
intermittently, and ventilation was adjusted to achieve a
PaCO2 between 35 and 45 mm Hg and a PaO2 of more than 50
mm Hg. Sodium bicarbonate was administered intermittently
to maintain a pH of more than 7.30. Normal saline solution
and red blood cells were administered to maintain atrial pres-
sures and hemoglobin concentrations at pre-CPB levels.
Blood from the femoral artery was obtained for ET-1 levels
before and 0.5, 1, 2, 4, and 6 hours after CPB. Blood was
obtained for plasma PD 156707 concentrations before and 4
and 6 hours after CPB. Four hours after CPB, the infusion of
PD 156707 was stopped, and the hemodynamic variables
were monitored for an additional 2 hours. All lambs were
killed with a lethal injection of sodium pentobarbital fol-
lowed by bilateral thoracotomy as described in the NIH
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Guidelines for the Care and Use of Laboratory Animals. All
protocols and procedures were approved by the Committee
on Animal Research of the University of California, San
Francisco.
Statistical analysis. The means ± standard deviation were
calculated for the baseline hemodynamic variables, systemic
arterial blood gases and pH, and plasma ET-1 and PD
156707 concentrations. The baseline hemodynamic variables
were compared between groups by the unpaired t-test. The
general hemodynamic variables, systemic arterial blood
gases and pH, and ET-1 concentrations were compared over
time within each study group by analysis of variance
(ANOVA) for repeated measures with an autoregressive
symmetric covariance structure. Adjustments for multiple
comparisons from baseline were made by the Dunnett pro-
cedure. The Tukey procedure was used for multiple compar-
isons across groups. The results from both groups were
pooled, and a linear regression analysis of the pulmonary
vascular resistance and mean pulmonary arterial pressure
with plasma ET-1 concentrations was performed to identify
possible relevant relations.
Results
The general hemodynamics of the 2 groups of lambs
before the initiation of CPB are presented in Table I.
Table I. General hemodynamics
Saline-treated shunted lambs PD 156707-treated shunted lambs 
(n = 5) (n = 6)
Age (days) 28.7 ± 2.5 32.8 ± 7.6
Weight (kg) 10.4 ± 1.3 11.8 ± 2.9
Hemoglobin (g/dL) 9.6 ± 1.6 9.1 ± 1.0
Mean pulmonary arterial pressure (mm Hg) 35.6 ± 6.1 29.2 ± 6.8
Mean systemic arterial pressure (mm Hg) 56.0 ± 12.1 59.3 ± 11.2
Pulmonary vascular resistance (mm Hg/mL/min/kg) 0.118 ± 0.06 0.087 ± 0.03
Pulmonary blood flow (mL/kg/min) 250.4 ± 81.7 241.3 ± 63.4
Heart rate (beats/min) 165.4 ± 26.3 161.2 ± 22.4
Left atrial pressure (mm Hg) 8.7 ± 3.8 9.3 ± 2.6
Right atrial pressure (mm Hg) 7.7 ± 1.5 5.8 ± 1.5
Pulmonary artery pressure/systemic artery pressure 0.66 ± 0.17 0.51 ± 0.15
Pulmonary blood flow/systemic blood flow 2.7 ± 1.0 3.2 ± 1.3
CPB time (min) 114.2 ± 12.8 131.7 ± 18.3
Values are mean ± SD; values in shunted lambs were obtained before closure of the vascular graft. There were no differences between the 2 groups.
Table II. The hemodynamic changes after CPB in saline-treated shunted lambs (n = 5)
Time after CPB (min)
Before CPB 15 30 60 120 180 240 300 360 
Pulmonary arterial 27.2±5.5 40.2±9.8* 36.2±7.9* 35.6±9.7* 35.4±1.8* 32.2±6.3* 33.8±6.1* 33.2±6.0* 30.0±5.8*
pressure (mm Hg)
Pulmonary vascular 0.148±0.06 0.309±0.16* 0.263±0.13* 0.252±0.14* 0.280±0.13* 0.280±0.18* 0.288±0.19 0.296±0.20* 0.193±0.09
resistance (mm Hg/mL
/min/kg)
Pulmonary blood flow 127.5±18.30 109.2±40.9 112.81±44.8 110.8±29.4 103.4±32.9 85.5±21.9* 92.1±28.7 89.8±28.3 99.6±26.4
(mL/kg/min)
Systemic arterial pressure 67.6±23.4 53.4±3.9* 53.2±12.3* 57.8±9.6 60.0±27.3 45.6±20.7* 44.2±17.1* 39.4±13.9* 40.5±10.2*
(mm Hg)
Heart rate (beats/min) 157.8±26.6 145.0±16.0 141.8±15.8 139.6±18.9 149.6±27.5 149.6±26.9 147.4±38.4 143.4±30.7 154.0±19.2
Left atrial pressure 9.0±0.0 10.8±1.9 10.2±2.1 9.8±2.1 9.8±1.0 10.8±1.6 11.2±2.6 10.4±3.9 11.0±4.2
(mm Hg)
Right atrial pressure 9.8±3.0 10.6±1.1 10.2±1.6 9.4±1.1 8.8±1.9 9.9±1.7 10.2±1.9 9.2±2.8 9.5±3.1
(mm Hg)
pH (units) 7.38±0.08 7.34±0.09 7.34±0.08 7.36±0.08 7.27±0.07* 7.31±0.04* 7.31±0.04* 7.31±0.05* 7.35±0.04
PaCO2 (mm Hg) 42.0±6.4 38.0±6.9 37.6±5.2 38.4±9.9 49.2±10.4 43.2±5.5 44.4±8.4 39.4±5.1 40.3±8.7
PaO2 (mm Hg) 58.0±5.8 68.4±11.2 83.8±18.7 74.6±27.6 82.2±57.5 70.6±26.1 68.6±19.2 62.8±16.9 59.5±14.1
Values are mean ± SD. 
*P < .05 vs before CPB (ANOVA).
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All lambs had an increase in oxygen saturation
between the right ventricle and distal pulmonary artery.
There were no differences in the general hemodynam-
ics between the 2 groups. In addition, systemic arterial
blood gases and pH were similar in both groups, and all
were within the normal range for the laboratory (data
not shown).
In saline-treated shunted lambs, both pulmonary vas-
cular resistance (P = .023) and mean pulmonary arteri-
al pressure (P = .002) increased over the 6-hour study
period after CPB. Pulmonary blood flow, mean sys-
temic arterial pressure, and systemic arterial pH were
intermittently decreased. Heart rate, left and right atri-
al pressure, PaCO2, and PaO2 were unchanged (Table II). 
The intravenous infusion of PD 156707 decreased
mean systemic arterial pressure from 61.3 ± 14.1 mm
Hg to 52.5 ± 12.8 mm Hg (P < .033). All other hemo-
dynamic variables were unchanged. Over the 4.5-hour
infusion period, plasma PD 156707 concentrations
remained over 500 ng/mL (from 546.5 ± 125.0 ng/mL
to 580.0 ± 211.0 ng/mL). Two hours after discontinua-
tion of the infusion, plasma concentrations decreased
to 97.2 ± 63.2 ng/mL (Fig 1). In PD 156707-treated
shunted lambs, pulmonary vascular resistance signifi-
cantly decreased after CPB (P = .0001). Mean pul-
monary arterial pressure was unchanged after CPB (P
= .493). Pulmonary blood flow increased, and mean
systemic arterial pressure decreased after 240 minutes.
Heart rate, left and right atrial pressure, systemic arter-
ial pH, PaCO2 and PaO2 were unchanged (Table III).
After CPB, both pulmonary vascular resistance and
mean pulmonary arterial pressure were greater in
saline-treated shunted lambs than in PD 156707-treat-
ed shunted lambs (Table IV) (Fig 2). After discontinu-
ation of the PD 156707 infusion (4 hours after CPB),
mean pulmonary arterial pressure and pulmonary vas-
Fig 1. The infusion of PD 156707 resulted in steady-state
plasma concentrations; these decreased over the 2 hours after
the infusion was discontinued. Values are mean ± SD; n = 5. 
Fig 2. PD 156707 blocks the increase in mean pulmonary
arterial pressure (top) and pulmonary vascular resistance
(bottom) in shunted lambs immediately after CPB. Values
are mean ± SD; n = 5 saline-treated shunted lambs; N = 6 PD
156707-treated shunted lambs. *P < .05 vs before CPB (time
0; ANOVA).
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cular resistance did not change. Throughout the study
period, the mean airway pressure, minute ventilation,
and FiO2 required to maintain the predetermined venti-
latory parameters were similar in saline-treated shunt-
ed lambs and in PD 156707-treated shunted lambs.
ET-1 concentrations. Before CPB, plasma ET-1 con-
centrations were similar in both groups of lambs. After
CPB, ET-1 concentrations increased in both groups of
lambs (Fig 3). One and 2 hours after CPB, ET-1 con-
centrations were greater in saline-treated shunted lambs
than in PD 156707-treated shunted lambs (P < .05).
There was a positive correlation between plasma ET-1
concentrations and pulmonary vascular resistance (r =
0.3; P = .0024) and mean pulmonary arterial pressure (r
= 0.4; P = .0001).
Discussion
The present study provides support for a role for ET-
1 and ETA receptor activation in the pathogenesis of
pulmonary hypertension after CPB. Pulmonary vascular
resistance, mean pulmonary arterial pressure, and plas-
ma ET-1 concentrations were increased after hypother-
mic CPB in 1-month-old lambs with pre-existing
increased pulmonary blood flow. The intravenous infu-
sion of PD 156707, a selective ETA receptor antagonist,
completely blocked the increase in pulmonary vascular
Table III. The hemodynamic changes after CPB in PD 156707-treated shunted lambs (n = 6)
Time after CPB (min)
Before CPB 15 30 60 120 180 240 300 360
Pulmonary arterial 22.0±3.5 19.8±4.3* 18.8±3.4* 17.7±3.3* 19.0±5.6 18.5±4.3* 18.7±5.0* 19.0±3.9* 19.8±3.9
pressure (mm Hg)
Pulmonary vascular 0.186±0.05 0.074±0.03* 0.078±0.03* 0.085±0.03* 0.128±0.06* 0.108±0.03* 0.106±0.04* 0.107±0.05* 0.122±0.07*
resistance (mm Hg/mL/
min/kg)
Pulmonary blood flow 84.8±5.3 150.9±20.9* 132.3±28.7* 121.2±29.6* 101.7±25.0* 105.5±20.7* 109.3±28.4* 115.9±26.5* 118.1±32.8
(mL/kg/min)
Systemic arterial pressure 52.5±12.8 60.8±8.9* 57.0±9.0 55.8±8.7 51.1±4.7 49.8±10.2 45.1±9.4* 45.3±6.3* 43.1±8.1*
(mm Hg)
Heart rate (beats/min) 151.8±6.9 154.0±21.8 149.3±19.9 150.8±20.2 154.7±16.7 152.8±12.0 157.7±11.2 159.8±16.4 166.8±18.9*
Left artrial pressure 6.4±2.0 8.5±2.2* 8.8±3.2* 7.7±2.1* 6.7±2.1 7.3±2.1 7.3±1.9 7.2±2.3 6.7±2.3
(mm Hg)
Right artrial pressure 5.6±2.2 8.5±1.9* 8.6±2.2* 6.8±1.5 6.7±1.5 6.8±1.3 7.0±1.2* 6.6±1.6 6.5±1.6
(mm Hg)
pH (units) 7.33±0.03 7.32±0.07 7.34±0.08 7.36±0.05 7.38±0.04 7.37±0.05 7.39±0.04* 7.38±0.05 7.38±0.07
PaCO2 (mm Hg) 45.5±5.5 44.3±15.0 45.3±11.1 43.0±8.1 41.5±5.0 43.5±6.9 41.7±5.5 43.5±5.0 44.0±8.1
PaO2 (mm Hg) 59.5±11.4 109.1±75.4* 87.1±39.1 73.8±13.0 61.0±6.6 52.5±5.3 52.8±2.3 50.5±4.5 49.8±1.5
Values are mean ± SD.
*P < .05 vs before CPB (ANOVA).




shunted lambs Saline-treated shunted lambs (n=5) after CPB (min)
(n=6) after 
CPB (min) 0 15 30 60 120 180 240 300 360
0 .981 .001 .006 .012 .014 .193 .059 .095 .403
15 .732 .000 .001 .001 .002 .036 .008 .015 .108
30 .521 .000 .000 .000 .001 .015 .003 .006 .05
60 .292 .000 .000 .000 .000 .005 .000 .002 .019
120 .575 .000 .000 .001 .001 .019 .004 .007 .061
180 .450 .000 .000 .000 .000 .011 .002 .004 .038
240 .485 .000 .000 .000 .000 .013 .003 .005 .044
300 .557 .000 .000 .001 .001 .017 .004 .007 .057
360 .732 .000 .001 .001 .002 .037 .008 .015 .108
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resistance and mean pulmonary arterial pressure after
CPB. The increase in plasma ET-1 concentration after
CPB correlated with the increase in pulmonary vascular
resistance and mean pulmonary arterial pressure.
An association between ET-1 and pulmonary hyper-
tensive disorders in humans has been well described. For
example, several studies demonstrate increased ET-1
concentrations in children with congenital heart disease
that is associated with increased pulmonary blood flow
and pulmonary hypertension.17 In addition, patients with
advanced pulmonary hypertension secondary to a vari-
ety of conditions display increased ET-1 gene expression
within the pulmonary vascular endothelial cells.18
Recent studies have suggested a role for ET-1 in the
pathophysiologic evidence for pulmonary hypertension
after CPB. For example, in children with congenital
heart disease and pulmonary hypertension, plasma con-
centrations of ET-1 are increased immediately after
CPB.8 In addition, in normal piglets, inhibition of
endothelin-converting enzyme-1 (the enzyme that con-
verts proendothelin into its functional form) attenuates
pulmonary hypertension after CPB.9
The hemodynamic effects of ET-1 are mediated by at
least 2 distinctive receptor populations, ETA and ETB,
the densities of which are different depending on the
vascular bed studied. The ETA receptors are located on
vascular smooth muscle cells and mediate vasocon-
striction, whereas the ETB receptors may be located on
endothelial cells and mediate both vasodilation and
vasoconstriction.7 In addition, a second subpopulation
of ETB receptors is located on smooth muscle cells and
mediate vasoconstriction.20 In lambs with pre-existing
increased pulmonary blood flow, the infusion of PD
145065 (a combined ETA and ETB receptor antagonist)
completely blocked the increase in pulmonary vascular
resistance after hypothermic CPB.10 However, the ET-
1 receptor subtype that mediates pulmonary vasocon-
striction after CPB has been unclear. A recent study in
piglets demonstrates a increase in ETB receptor expres-
sion in lung parenchyma after hypothermic CPB, sug-
gesting a possible role for ETB receptor-mediated pul-
monary vasoconstriction.21 In the present study, we
have shown that selective ETA receptor blockade com-
pletely blocks pulmonary vasoconstriction after CPB,
suggesting that pulmonary hypertension after CPB is
mediated, at least in part, through the ETA receptor
activation. 
To selectively block ETA receptor activity during and
after CPB, we used PD 156707, a non-peptide ETA
receptor antagonist. PD 156707 is highly selective for
the ETA receptor and inhibits the binding of 125I-ET-1 to
cloned human ETA receptor and ETB receptor with Ki
values of 0.17 and 133.8 nmol/L, respectively.15 In rab-
bits, PD 156707 infusion rates of 0.03 mg/kg/h com-
pletely blocked the vasoconstricting effects of exoge-
nous ET-1, with corresponding plasma concentrations
that were less than 0.05 m g/mL (10–7 mol/L).14,16 We
have also performed several preliminary studies in
lambs that demonstrate that PD 156707 infusion rates of
1.0 mg/kg/h completely and selectively block the vaso-
constricting effects of exogenous ET-1 (250 ng/kg) and
produce stable plasma concentrations within 30 minutes
of initiating the infusion (data not shown). Therefore in
the present study we used an infusion rate of 1.0
mg/kg/h that was initiated 30 minutes before the initia-
tion of CPB. As demonstrated in Fig 1, these infusions
resulted in stable plasma concentration of more than
500 ng/mL throughout the infusion period. 
After the discontinuation of the PD 156707 infusion,
plasma concentrations quickly decreased to subthera-
peutic values. We monitored the hemodynamic vari-
ables for 2 hours after discontinuation of the infusion
and found that despite persistently increased plasma
ET-1 concentrations, pulmonary vascular resistance
and pulmonary arterial pressure did not increase. This
most likely represents prolonged ETA receptor block-
Fig 3. After CPB, plasma ET-1 concentrations are increased
in all lambs. At 1 and 2 hours, plasma ET-1 is significantly
higher in the saline-treated shunted lambs. Values are mean ±
SD; n = 5 saline-treated shunted lambs; n = 6 PD 156707-
treated shunted lambs. *P < .05 vs before CPB (time 0;
ANOVA).
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ade and/or other alterations in vascular reactivity
induced by prolonged ETA receptor blockade. For
example, several studies demonstrate physiologic inter-
actions between the ET-1, nitric oxide, and the
prostaglandin pathways.22
After CPB, plasma ET-1 concentrations increased in
both groups of lambs. This has been previously noted
in patients with pulmonary hypertension and congeni-
tal heart disease.8 The cause of increased ET-1 concen-
trations after CPB is unknown, but several factors asso-
ciated with CPB (eg, surgical stress, hypothermia,
alveolar hypoxia, and cardiogenic shock) are known to
increase ET-1 concentrations.23-25 Because plasma con-
centrations of ET-1 increased more in saline-treated
lambs than in PD 156707-treated lambs, there was a
positive correlation between the increase in pulmonary
vascular resistance after CPB and the plasma ET-1 con-
centration. However, this positive correlation has been
inconsistent in other studies. For example, we have pre-
viously demonstrated that normal lambs and shunted
lambs have similar increases in plasma ET-1 concen-
trations after CPB, but shunted lambs have a much
greater increase in pulmonary vascular resistance.10
Although circulating ET-1 concentrations are a marker
of ET-1 production, circulating ET-1 levels may be less
important than the higher tissue concentrations
achieved by local ET-1 release.26 In addition, the phys-
iologic effects of ET-1 are dependent on the pre-exist-
ing status of the pulmonary circulation.11,27 For exam-
ple, increased pulmonary blood flow and pulmonary
hypertension are associated with increased ETA recep-
tor and decreased ETB receptor expression.11,27
Therefore significantly greater ET-1–induced pul-
monary vasoconstriction may occur under these condi-
tions even if plasma and local tissue concentrations are
similar.
Previously, we have shown that the increase in pul-
monary vascular resistance after CPB is dependent on
the pre-existing status of the pulmonary circulation;
pulmonary vascular resistance increased in shunted
lambs after CPB but remained unchanged in age-
matched control lambs.10 Therefore we used shunted
lambs for the current study. However, it should be
noted that because these shunted lambs are young, with
only moderate vascular smooth muscle abnormalities,
they displayed only moderate increases in pulmonary
vascular resistance after CPB. The efficacy of ETA
receptor blockade in patients with more advanced pul-
monary vascular disease warrants further investigation. 
In summary, hypothermic CPB increased pulmonary
vascular resistance, mean pulmonary arterial pressure,
and plasma ET-1 concentrations in lambs with pre-
existing increased pulmonary blood flow and pul-
monary hypertension. In addition, we found that pre-
treatment with a selective ETA receptor antagonist
completely blocked the increase in pulmonary vascular
resistance and mean pulmonary arterial pressure after
hypothermic CPB. These data suggest an important
role for ET-1 and ETA receptor activation in the patho-
physiologic evidence of pulmonary hypertension after
CPB and its associated increased pulmonary vascular
reactivity. In addition to the alterations induced in the
pulmonary circulation, ischemia to the brain and kid-
neys is a significant source of morbidity and death in
children with congenital heart disease after hypother-
mic CPB.12 ET-1 produces potent vasoconstriction in
both the cerebral and renal circulations, and recent data
demonstrate that treatment with ETA receptor blockers
decreases ischemic injury in animal models of cerebral
and renal ischemia.28-30 Therefore the potential use of
ETA receptor blockers during CPB may have signifi-
cant clinical benefits and warrants further study. 
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Discussion
Dr F. Mark Lupinetti (Seattle, Wash). This elegant study
nicely convinces one of the validity of the investigators’
hypotheses that ET-1 is an important mediator of pulmonary
hypertension in this model and that ETA receptor blockade
effectively blunts this hemodynamic response. The elevations
in pulmonary vascular resistance and pulmonary artery pres-
sure though statistically significant were relatively modest.
Could you speculate as to the possible influence of this find-
ing on the thought regarding patients with more severe
degrees of pulmonary hypertension? Do you believe that the
patient with the markedly elevated pulmonary hypertensive
crisis in the postoperative period has a quantitatively greater
elaboration of ET-1, or is it a greater density of ET-1 recep-
tors? Or perhaps should we be considering mediators other
than ET-1 to explain the more clinically problematic situation?
Dr Petrossian. In the current study, both the control and
the study lambs had a modest degree of pulmonary hyperten-
sion. In a previous study using this same model, the pul-
monary artery pressure was up to 79% systemic. Patients
with more advanced degrees of pulmonary hypertension are
usually exposed to a longer period of increased pulmonary
blood flow than the rather short (1-month) duration that the
lambs in our experiment were exposed to. The severe degree
of pulmonary hypertension in these patients is usually due to
a combination of reversible and irreversible changes in the
pulmonary vasculature.
Reversible pulmonary hypertensive disease in the setting of
increased pulmonary blood flow is mediated by a complex
interaction between nitric oxide and endothelin cascades. In
the current study we have focused on the endothelin pathway
alone. The mechanism of endothelin-mediated pulmonary
hypertension is incompletely understood. There is consider-
able evidence, both clinically and experimentally, that
endothelin gene expression is up-regulated in patients with
advanced pulmonary hypertension. There is also evidence
that ETB receptors are involved in clearance of endothelin
and that their expression is attenuated, thereby resulting in
increased endothelin levels. Using our model, we have also
shown (work currently in progress) that there is increased
gene expression of ETA receptors.
Dr Bradley Allen (Chicago, Ill). This is an elegant model.
What happens in systemic pressures when you infuse
PD156707? You told us what happened to the pulmonary
pressures. Did you see any side effects in your systemic pres-
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sures? I would expect CPB to cause a systemic inflammatory
response, not to the lungs alone, but to the whole body. This
can increase ET-1 expression, and I would have thought that
you would also see an effect systemically.
Dr Petrossian. In response to your first question, we saw a
mild and clinically insignificant drop in systemic arterial pres-
sure after starting PD156707 and before instituting CPB. After
bypass there was a significant drop in systemic pressures com-
pared with levels before bypass, but this occurred to a similar
extent in both the study lambs and the control lambs and was
therefore not related to endothelin receptor blockade. The selec-
tive effect of PD156707 and the pulmonary rather than systemic
artery pressure may be related to the more dense concentration
of endothelin receptors on the pulmonary vasculature.
In response to your second question, we did not examine
the lungs histologically, and we also did not assess endothe-
lial cell function physiologically. We therefore cannot specu-
late on whether the favorable effects of PD 156707 on pul-
monary artery pressures after bypass were mediated by
protection of the lungs from the injurious effects of the
inflammatory response accompanying CPB or by preserva-
tion of endothelial cell function.
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